🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which spec...
Status
Recruiting
Location
The Second Affiliated Hospital Zhejiang University
Start Date
2024-10-03
Trial ID
NCT06825624
Treatments Being Tested
This is a multicenter, randomized, open-label, controlled phase III clinica...
Status
Not Yet Recruiting
Location
Multiple Locations
Start Date
2026-07-31
Trial ID
NCT07621601
Treatments Being Tested
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which spec...
Status
Not Yet Recruiting
Location
Multiple Locations
Start Date
2024-12-20
Trial ID
NCT06699576
Treatments Being Tested
This is a phase 2,open-label, multi-center study to evaluate the efficacy, ...
Status
Withdrawn
Location
Multiple Locations
Start Date
2024-11-30
Trial ID
NCT06052423
Treatments Being Tested
This will be an open-label Phase 0/1 study that will enroll approximately 1...
Status
Recruiting
Location
St. Joseph's Hospital and Medical Center
Start Date
2026-02-11
Trial ID
NCT07268053
Treatments Being Tested
This is a phase II, multicentre clinical study investigating HS-20093 or SH...
Status
Recruiting
Location
Nanjing Drum Tower Hospital
Start Date
2025-12-08
Trial ID
NCT07230106
This is a Phase Ib study that will evaluate the Safety, Tolerability , Phar...
Status
Not Yet Recruiting
Location
The Second Affiliated Hospital of Zhejiang University School of Medicine
Start Date
2025-05-30
Trial ID
NCT06963502
HS-20093 is a humanized IgG1 antibody-drug conjugate (ADC) which specifical...
Status
Recruiting
Location
Anhui Provincial Cancer Hospital
Start Date
2024-02-06
Trial ID
NCT06112704
Treatments Being Tested
This study will evaluate the efficacy, safety and tolerability of HS-20093 ...
Status
Not Yet Recruiting
Location
Multiple Locations
Start Date
2024-09-30
Trial ID
NCT06526624
Treatments Being Tested
HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific ...
Status
Recruiting
Location
Tianjin Medical University Cancer Institute & Hospital
Start Date
2024-12-14
Trial ID
NCT06621563